The Critical Choice of Animal Models in Nanomedicine Safety Assessment: A Lesson Learned From Hemoglobin-Based Oxygen Carriers.

Frontiers in Immunology
Péter Bedöcs, János Szebeni

Abstract

Intravenous injection of nanopharmaceuticals can induce severe hypersensitivity reactions (HSRs) resulting in anaphylactoid shock in a small percentage of patients, a phenomenon explicitly reproducible in pigs. However, there is a debate in the literature on whether the pig model of HSRs can be used as a safety test for the prediction of severe adverse reactions in humans. Given the importance of using appropriate animal models for toxicity/safety testing, the choice of the right species and model is a critical decision. In order to facilitate the decision process and to expand the relevant information regarding the pig or no pig dilemma, this review examines an ill-fated clinical development program conducted by Baxter Corporation in the United States 24 years ago, when HemeAssist, an αα (diaspirin) crosslinked hemoglobin-based O2 carrier (HBOC) was tested in trauma patients. The study showed increased mortality in the treatment group relative to controls and had to be stopped. This disappointing result had far-reaching consequences and contributed to the setback in blood substitute research ever since. Importantly, the increased mortality of trauma patients was predicted in pig experiments conducted by US Army scientists, yet...Continue Reading

References

Jan 1, 1992·Biomaterials, Artificial Cells, and Immobilization Biotechnology : Official Journal of the International Society for Artificial Cells and Immobilization Biotechnology·D NelsonK Burhop
Jan 1, 1992·Biomaterials, Artificial Cells, and Immobilization Biotechnology : Official Journal of the International Society for Artificial Cells and Immobilization Biotechnology·D NelsonA Loewen
Jan 1, 1992·Biomaterials, Artificial Cells, and Immobilization Biotechnology : Official Journal of the International Society for Artificial Cells and Immobilization Biotechnology·J R HessR M Winslow
Apr 1, 1991·Journal of Applied Physiology·J R HessR M Winslow
Jan 1, 1995·Artificial Cells, Blood Substitutes, and Immobilization Biotechnology·J R Hess
Jan 1, 1994·Artificial Cells, Blood Substitutes, and Immobilization Biotechnology·J R HessV Coppes
Apr 1, 1993·Journal of Applied Physiology·J R HessW W Brinkley
Oct 1, 1996·Transfusion Medicine Reviews·J R Hess, R F Reiss
Sep 20, 2000·American Journal of Physiology. Heart and Circulatory Physiology·J SzebeniC R Alving
Oct 11, 2005·American Journal of Physiology. Heart and Circulatory Physiology·János SzebeniRolf Bünger
Jan 3, 2007·Seminars in Hematology·Robert M Winslow
Jul 7, 2007·Journal of Liposome Research·János SzebeniYezheckel Barenholz
Apr 30, 2008·JAMA : the Journal of the American Medical Association·Charles NatansonSidney M Wolfe
Jul 10, 2008·Nature Biotechnology·Charlie Schmidt
Oct 28, 2009·Anesthesiology·Toby A SilvermanUNKNOWN Planning Committee and the Speakers
Nov 12, 2009·Transfusion·Toby A Silverman, Richard B Weiskopf
Jun 28, 2011·Nanomedicine : Nanotechnology, Biology, and Medicine·János SzebeniYechezkel Barenholz
Jan 3, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Natalia R KuznetsovaChristian Grandfils
Mar 17, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·János SzebeniYechezkel Barenholz
Jul 24, 2012·Advanced Drug Delivery Reviews·János SzebeniRudolf Urbanics
Jun 7, 2014·Pharmacoepidemiology and Drug Safety·Eric D WeinhandlRobert N Foley
Aug 16, 2014·Anesthesia and Analgesia·Peter BedocsChester C Buckenmaier
Aug 26, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·László DézsiJános Szebeni
Jan 7, 2016·Nanomedicine : Nanotechnology, Biology, and Medicine·Simon BugnaBert Müller
Aug 15, 2017·Journal of Controlled Release : Official Journal of the Controlled Release Society·Marzia BuscemaBert Müller
Dec 6, 2017·Journal of Controlled Release : Official Journal of the Controlled Release Society·Tamás FülöpJános Szebeni
May 24, 2018·Nanomedicine·S Moein Moghimi, Dmitri Simberg
Sep 27, 2018·Drugs·Sheridan M Hoy
Oct 3, 2018·Advanced Drug Delivery Reviews·William C ZamboniMarina A Dobrovolskaia
Oct 24, 2018·Nature Nanotechnology·Janos SzebeniMarina A Dobrovolskaia
Mar 19, 2019·International Journal of Nanomedicine·Erik ŐrfiGábor Szénási
Apr 4, 2019·The Journal of Pharmacology and Experimental Therapeutics·S Moein MoghimiA Christy Hunter
Jul 12, 2019·Journal of Controlled Release : Official Journal of the Controlled Release Society·Tamás FülöpJános Szebeni
Sep 12, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·László DézsiGábor Szénási

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Software Mentioned

HemeAssist
HemAssist

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Related Papers

Gan to kagaku ryoho. Cancer & chemotherapy
Jun TaniguchiMasashi Hashimoto
Journal of Patient Safety
Kimberly G BlumenthalElizabeth Mort
Current Opinion in Allergy and Clinical Immunology
Josefina Cernadas
© 2021 Meta ULC. All rights reserved